• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

(CDK9-IN-5)

1

Identification

CDK9-IN-5 CDK9-IN-5
Name CDK9-IN-5
Formula C39H36N6O10
MW 748.74
CAS No.
EINECS
Smiles C(NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)(=O)CCCCCCCN1C=C(COC2C3OC(C4=CC=CC=C4)=CC(=O)C=3C(O)=CC=2O)N=N1
Synonyms
InChI InChI=1S/C39H36N6O10/c46-27-18-29(48)35(36-34(27)28(47)19-30(55-36)22-10-5-4-6-11-22)54-21-23-20-44(43-42-23)17-8-3-1-2-7-14-31(49)40-25-13-9-12-24-33(25)39(53)45(38(24)52)26-15-16-32(50)41-37(26)51/h4-6,9-13,18-20,26,46,48H,1-3,7-8,14-17,21H2,(H,40,49)(H,41,50,51)
2

Introduction

CDK9-IN-5 (Compound 11c) is a CDK9 inhibitor, which inhibits MCF-7 (CDK9-rich) cell lines with an IC50 of 17±1.9 μM. Cyclin-dependent kinase 9 (CDK9) is a serine (Ser)/threonine kinase which forms a subunit of the P-TEFb complex with cyclin T. It can interact with many transcription factors (TFs) and regulate the expression of antiapoptotic proteins for the survival of cancer cells.

Background Information

3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB100166943

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
7

Safety Data of CDK9-IN-5

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AMEDCHEM CHINA
10

Related Products

Other Forms of

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

CDK9-IN-5

Tags: buy CDK9-IN-5 IC50 | CDK9-IN-5 price | CDK9-IN-5 cost | CDK9-IN-5 solubility | CDK9-IN-5 purchase | CDK9-IN-5 manufacturer | CDK9-IN-5 research buy | CDK9-IN-5 order | CDK9-IN-5 MSDS | CDK9-IN-5 chemical structure | CDK9-IN-5 Storage condition | CDK9-IN-5 molecular weight | CDK9-IN-5 mw | CDK9-IN-5 datasheet | CDK9-IN-5 supplier | CDK9-IN-5 cell line | CDK9-IN-5 NMR | CDK9-IN-5 MS | CDK9-IN-5 IR | CDK9-IN-5 solubility | CDK9-IN-5 Safe information | CDK9-IN-5 Qc and Spectral Information | CDK9-IN-5 Clinical Information | CDK9-IN-5 Clinical Trial | CDK9-IN-5 Route of Synthesis | CDK9-IN-5 storage condition | CDK9-IN-5 diseases and conditions | CDK9-IN-5 flash point | CDK9-IN-5 boiling point | CDK9-IN-5 melting point | CDK9-IN-5 storage condition | CDK9-IN-5 brand